Philip Johnson
Net worth: 14 M $ as of 2026-08-30
Net worth: 14 M $ as of 2026-08-30
Philip L.
Johnson is currently Director at The American Chamber of Commerce in Japan, Director at Dermira, Inc. since 2020, President at DICE Therapeutics, Inc. since 2023, and Chief Financial Officer & Executive Vice President at both Jazz Pharmaceuticals Plc and Jazz Pharmaceuticals, Inc. since 2024.
Former roles include Chief Executive Officer at ARMO Biosciences, Inc., President & Director at Akouos, Inc., Sigilon Therapeutics, Inc., and POINT Biopharma Global, Inc., President & General Manager at Eli Lilly Italia SpA, and Treasurer & Senior Vice President-Finance at Eli Lilly & Co. Education includes undergraduate studies at the University of Illinois and graduate studies at Kellogg School of Management.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-29 | 56,431 ( 0.09% ) | 14 M $ | 2026-08-30 |
| Companies | Position | Start |
|---|---|---|
| DERMIRA, INC. | Director/Board Member | 2020-02-19 |
| DICE THER | President | 2023-08-08 |
| JAZZ PHARMACEUTICALS PLC | Director of Finance/CFO | 2024-02-29 |
The American Chamber of Commerce in Japan
The American Chamber of Commerce in Japan Miscellaneous Commercial ServicesCommercial Services Chamber of Commerce | Director/Board Member | - |
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Director of Finance/CFO | 2024-02-29 |
| Companies | Position | End |
|---|---|---|
| ELI LILLY AND COMPANY | Investor Relations Contact | 2017-12-31 |
| POIT BIOP | President | - |
| SIGILON THERAPEUTICS, INC. | President | - |
| AKOUOS | President | - |
| ░░░░ ░░░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 13 |
|---|---|
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Health Technology |
University of Illinois
University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The American Chamber of Commerce in Japan
The American Chamber of Commerce in Japan Miscellaneous Commercial ServicesCommercial Services Chamber of Commerce | Commercial Services |
Eli Lilly Italia SpA
Eli Lilly Italia SpA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Dermira, Inc.
Dermira, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products to patients living with chronic skin conditions | Health Technology |
Jazz Pharmaceuticals Plc
Jazz Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of pharmaceutical products to treat neurological disorders | Health Technology |
Kellogg School of Management
Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ARMO BioSciences, Inc.
ARMO BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapy for treatment of cancer | Health Technology |
DICE Therapeutics, Inc.
DICE Therapeutics, Inc. BiotechnologyHealth Technology Develops oral immunology and other therapeutic products | Health Technology |
Sigilon Therapeutics, Inc.
Sigilon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics and functional cures for patients with chronic diseases | Health Technology |
Akouos, Inc.
Akouos, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a genetic medicine company that develops adeno-associated viral vector-based gene therapies for sensorineural hearing loss | Commercial Services |
POINT Biopharma Global, Inc.
POINT Biopharma Global, Inc. BiotechnologyHealth Technology Develops radioligand therapies for the treatment of cancer | Health Technology |
Select your edition
All financial news and data tailored to specific country editions